www.amphionplc.com
Amphion builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.
Amphion has a significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.
Amphion Innovations CEO buys 65,000 more shares
Amphion Innovations (LSE: AMP) told investors that its chief executive Richard Morgan has increased his stake in the company, purchasing 50,000 shares at 15p per share and 15,000 at 16p. Consequently, Morgan now owns approximately 23.7 million shares representing 17.967% of Amphion’s issued share capital.
Earlier this month, Amphion released positive results for the year ended 31 December 2009. Amphion increased revenues by 22% to US$8.6m, subsequently gross profits increased almost 70% to US$5.8m.
The specialist investment and commercialisation company narrowed operating losses to US$892,937 during the year, compared to a US$3.4m loss in 2008.
For the full-year, reported Net Asset Value (NAV) per Share was US $0.42, compared to US$0.44 in the previous financial year. Additionally, Amphion said it should be noted that its intellectual property assets, which are valued at amortised cost, are producing sizable levels of gross income, which the company believes will continue in the future and could lead to an increase in value.
Amphion builds shareholder value in high growth companies in the medical and technology sectors by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Currently there are eight partner companies developing proven technologies targeting substantial commercial marketplaces in excess of US$1 billion.
